Results 171 to 180 of about 50,850 (292)

Topical Cycling and Systemic Eligibility in Patients With Psoriasis in Japan

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Topical therapy is the typical first‐line treatment for psoriasis, with the International Psoriasis Council recommending systemic therapy for patients with body surface area > 10%, high‐impact site involvement, or topical therapy failure. A recent Japanese Delphi Consensus Study proposed a definition for topical failure that considers time on ...
Akimichi Morita   +6 more
wiley   +1 more source

Comorbidity burden in the first three years after diagnosis in patients with rheumatoid arthritis, psoriatic arthritis or spondyloarthritis: a general practice registry-based study. [PDF]

open access: yesRMD Open, 2021
Stouten V   +9 more
europepmc   +1 more source

Treatment Patterns and Pathways of Systemic Drug Therapy in Patients With Plaque, Erythrodermic, and Generalized Pustular Psoriasis: A Retrospective Cohort Study in Japan

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Systemic psoriasis treatment options have rapidly expanded in Japan, including the approval of tyrosine kinase 2 and interleukin‐36 receptor inhibitors in 2022. However, contemporary real‐world treatment patterns across plaque, erythrodermic, and generalized pustular psoriasis remain incompletely characterized.
Yayoi Tada   +9 more
wiley   +1 more source

Redefining “Comorbidity” in Dermatology: Beyond Terminology, Lessons From Other Specialties

open access: yes
JEADV Clinical Practice, EarlyView.
Patricia Garbayo‐Salmons   +1 more
wiley   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

open access: yesAllergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter   +20 more
wiley   +1 more source

Safety of Venom Immunotherapy in Pregnancy: A Multicentre Study

open access: yesAllergy, EarlyView.
Venom immunotherapy (VIT) during pregnancy, when maintenance dose is well tolerated, can be continued. No increased risk of adverse effects to VIT or safety concerns for the pregnancy or the newborns were observed. No decreased efficacy of VIT, in case of re‐stings, was reported.
Matteo Martini   +20 more
wiley   +1 more source

Psoriatic arthritis mutilans [PDF]

open access: yesQJM: An International Journal of Medicine, 2020
J Samanta, A Chattopadhyay, A Sharma
openaire   +2 more sources

Home - About - Disclaimer - Privacy